A Phenogenetic Axis that Modulates Clinical Manifestation and Predicts Treatment Outcome in Primary Myeloid Neoplasms

调控原发性髓系肿瘤临床表现并预测治疗结果的表型发生轴

阅读:1
作者:Qiujin Shen # ,Yahui Feng # ,Xiaowen Gong # ,Yujiao Jia # ,Qingyan Gao # ,Xiaokang Jiao # ,Saibing Qi # ,Xueou Liu # ,Hui Wei # ,Bingqing Huang ,Ningning Zhao ,Xiaoqiang Song ,Yueshen Ma ,Shihao Liang ,Donglei Zhang ,Li Qin ,Ying Wang ,Shiqiang Qu ,Yao Zou ,Yumei Chen ,Ye Guo ,Shuhua Yi ,Gang An ,Zengtao Jiao ,Song Zhang ,Linfeng Li ,Jun Yan ,Huijun Wang ,Zhen Song ,Yingchang Mi ,Lugui Qiu ,Xiaofan Zhu ,Jianxiang Wang ,Zhijian Xiao ,Junren Chen

Abstract

Although the concept of "myeloid neoplasm continuum" has long been proposed, few comparative genomics studies directly tested this hypothesis. Here we report a multi-modal data analysis of 730 consecutive newly diagnosed patients with primary myeloid neoplasm, along with 462 lymphoid neoplasm cases serving as the outgroup. Our study identified a "Pan-Myeloid Axis" along which patients, genes, and phenotypic features were all aligned in sequential order. Utilizing relational information of gene mutations along the Pan-Myeloid Axis improved prognostic accuracy for complete remission and overall survival in adult patients of de novo acute myeloid leukemia and for complete remission in adult patients of myelodysplastic syndromes with excess blasts. We submit that better understanding of the myeloid neoplasm continuum might shed light on how treatment should be tailored to individual diseases. Significance: The current criteria for disease diagnosis treat myeloid neoplasms as a group of distinct, separate diseases. This work provides genomics evidence for a "myeloid neoplasm continuum" and suggests that boundaries between myeloid neoplastic diseases are much more blurred than previously thought.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。